FDA issues EUA for remdesivir to treat severe COVID-19 cases

By The Science Advisory Board staff writers

May 4, 2020 -- The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir to be used for the treatment of COVID-19. The EUA was issued to Gilead Sciences on Friday, May 1.

The emergency authorization allows for remdesivir to be distributed in the U.S. and administered intravenously by healthcare providers to treat suspected or confirmed severe COVID-19 cases, according to the agency. Severe cases are defined as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support.

The authorization was evaluated based on limited safety and effectiveness information from a clinical trial (the Adaptive COVID-19 Treatment Trial). It was determined that remdesivir may be effective in treating COVID-19 -- the lack of alternative treatments and the potential benefits of treating the disease outweigh the known and potential risks of the drug's use.

Possible side effects of remdesivir include increased levels of liver enzymes -- which may be a sign of inflammation or damage to cells in the liver -- and infusion-related reactions, which may include low blood pressure, nausea, vomiting, sweating, and shivering. The EUA requires that information and fact sheets be made available to healthcare providers and patients.

There are currently over 15 clinical trials in various stages evaluating the use of remdesivir for COVID-19 globally.

COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the...
Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene...
New antiviral drug could work against many viruses, including SARS-CoV-2
An antiviral drug called EIDD-2801 that's in preclinical testing has potential to be developed into the silver bullet that medical professionals seek...
Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...
3 reasons the coronavirus outbreak has been so severe
WASHINGTON, DC - Why has the current outbreak of coronavirus been so severe compared with past epidemics of viral respiratory diseases? It has to do with...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
BioProcess International Europe
July 13-17
Central European Time Zone (CET) Netherlands
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter